Completed Clinical Trials

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma

Estimated Enrollment: 89

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: MORAb-009-003 Amatuximab

Study First Received: August 19, 2008

Last Updated: November 13, 2015

Estimated Primary Completion Date: June 2011


Primary Outcome Measures:

Progression free survival using the EORTC modified RECIST criteria.|Overall response, duration of survival, overall survival and safety.

Sponsors and Collaborators:


Website Link:

Leave a Reply

Call Now ButtonCall Now